Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas Sales Dip 4.4% on Forex Moves, Japan Biz Dented by Price Cuts
Astellas Pharma saw its group sales diminished 4.4% to 1.31 trillion yen in the year ended March 2017, dragged down by the stronger yen and Japan’s biennial drug price revision in April last year, the company said on April 27.…
To read the full story
Related Article
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
- Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
November 1, 2017
- Astellas Looking to Xtandi Growth Outside US: President
April 28, 2017
- Astellas Logs Record Earnings on Bullish Xtandi in FY2015
May 12, 2016
BUSINESS
- G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
- Nxera’s Partner Earns Taiwan Approval for Daridorexant
April 15, 2026
- Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
- Eylea Biosimilar Supply Curbed amid Originator Disruption
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…